We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Cronos Group (CRON - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cronos Group is a member of our Medical group, which includes 920 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Cronos Group is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CRON's full-year earnings has moved 175% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CRON has gained about 28.5% so far this year. Meanwhile, the Medical sector has returned an average of 3.5% on a year-to-date basis. This shows that Cronos Group is outperforming its peers so far this year.
Curaleaf Holdings, Inc. (CURLF - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 29.4%.
For Curaleaf Holdings, Inc., the consensus EPS estimate for the current year has increased 103.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Cronos Group belongs to the Medical - Drugs industry, a group that includes 139 individual companies and currently sits at #154 in the Zacks Industry Rank.
In contrast, Curaleaf Holdings, Inc. falls under the Medical - Products industry. Currently, this industry has 86 stocks and is ranked #97.
Investors interested in the Medical sector may want to keep a close eye on Cronos Group and Curaleaf Holdings, Inc. as they attempt to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Cronos Group (CRON - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cronos Group is a member of our Medical group, which includes 920 different companies and currently sits at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Cronos Group is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for CRON's full-year earnings has moved 175% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, CRON has gained about 28.5% so far this year. Meanwhile, the Medical sector has returned an average of 3.5% on a year-to-date basis. This shows that Cronos Group is outperforming its peers so far this year.
Curaleaf Holdings, Inc. (CURLF - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 29.4%.
For Curaleaf Holdings, Inc., the consensus EPS estimate for the current year has increased 103.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Cronos Group belongs to the Medical - Drugs industry, a group that includes 139 individual companies and currently sits at #154 in the Zacks Industry Rank.
In contrast, Curaleaf Holdings, Inc. falls under the Medical - Products industry. Currently, this industry has 86 stocks and is ranked #97.
Investors interested in the Medical sector may want to keep a close eye on Cronos Group and Curaleaf Holdings, Inc. as they attempt to continue their solid performance.